2020 ASCO Update on High-risk Resectable Stage III Melanoma: Can 2 Cycles of Neoadjuvant Ipi + Nivo Induce High pCR and Omit TLND to Reduce Surgical Morbidity?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ASCO Update on High-risk Resectable Stage III Melanoma: Can 2 Cycles of Neoadjuvant Ipi + Nivo Induce High pCR and Omit TLND to Reduce Surgical Morbidity?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Gary Doolittle

194 views

July 22, 2020

0 Comments

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner

23:09

Total Health

Key Updates in Skin Melanoma

Feat. R. Seedor

06:39

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…

Feat. J. Luke

17:39

Melanoma Bridge 2023

Major Emerging Paradigm Shifts That Will Change Melanoma Management …

Feat. A. Eggermont

24:14

Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher

08:38

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cem…

Feat. T. Panella

19:52

OncoAlert

Melanoma Updates: Adjuvant Therapy, Advanced Disease, Uveal Melanoma…

Feat. A. Betof Warner

08:46

Sapna Patel

Neoadjuvant Immunotherapy in the Treatment of Melanoma: What Do We K…

52:19

Winship Melanoma and Cutaneous Oncology Symposium

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Feat. S. Patel

08:27

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Significant Durable Response With Fianlim…

Feat. O. Hamid

30:29

NYU Langone

Updates in Treatment with Immunotherapy for Melanoma and Related Mal…

Feat. J. Weber

20:55

2023 West Oncology Conference

2023 West Oncology Conference: Melanoma Updates

Feat. M. Mooradian

04:45

Sapna Patel

Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…

25:10

Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Immunotherapy Combinations in Melanoma in 2024

Feat. J. Moyers

14:36

Melanoma Bridge 2023

Treating PD-1 Refractory Melanoma With TIL Therapy vs. Nivo+Ipi: Pro…

Feat. J. Smithy

16:00

AACR 2023 Conference Coverage

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resec…

Feat. J. Weber

18:54

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Where Are We Going in Uveal, Mucosal & …

Feat. O. Hamid

10:39

University of Colorado Department of Medicine

Cardio-Oncology: Definitions and Scope

Feat. L. Kondapalli

13:31

Melanoma Bridge 2023

What Is the Best Initial Treatment for Unresectable Mucosal Melanoma…

Feat. J. Luke

13:51

Hardeep Phull

Login

Login

Join VuMedi

2020 ASCO Update on High-risk Resectable Stage III Melanoma: Can 2 Cycles of Neoadjuvant Ipi + Nivo Induce High pCR and Omit TLND to Reduce Surgical Morbidity?

Related Content